Bionano Genomics has a quick ratio of 1.13. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bionano Genomics's Quick Ratio or its related term are showing as below:
BNGO'
s Quick Ratio Range Over the Past 10 Years
Min: 0.33 Med: 2.77 Max: 51.22
Current: 1.13
During the past 8 years, Bionano Genomics's highest Quick Ratio was 51.22. The lowest was 0.33. And the median was 2.77.
BNGO's Quick Ratio is ranked worse than 71.74% of 867
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs BNGO: 1.13
Bionano Genomics Quick Ratio Historical Data
The historical data trend for Bionano Genomics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bionano Genomics's Quick Ratio
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics's Quick Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Quick Ratio falls into.
Bionano Genomics Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Bionano Genomics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (NAS:BNGO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Bionano Genomics Quick Ratio Related Terms
Thank you for viewing the detailed overview of Bionano Genomics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Bionano Genomics (Bionano Genomics) Business Description
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BNGO has been successfully added to your 